A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer.

Trial Profile

A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 20 Jan 2018 Results of a post-hoc analysis assessing the impact of primary tumour location on outcomes in patients with RAS wild-type metastatic colorectal cancer undergoing first-line panitumumab plus FOLFIRI treatment, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Oct 2016 Results of retrospective analysis assessing impact of tumour RAS/BRAF status in a first-line study of panitumumab in combination with FOLFIRI published in the British Journal of Cancer.
    • 02 Jun 2015 Results of analysis of relationship between AREG expression and treatment outcome presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top